目的分析宫颈癌术前新辅助化疗—动脉灌注的疗效。
Objective To analyze the therapeutic effect of arterial perfusion and neoadjuvant chemotherapy on cervical cancer.
结论术前新辅助化疗可提高食管癌手术的切除率并不增加术后并发症。
Conclusion Patients of esophageal carcinoma, neoadjuvant chemotherapy can increased the resectability rate, meanwhile cannot increase postoperative complications and mortality.
目的探讨术前新辅助化疗对乳腺癌的疗效及提高患者术后生存率的作用。
To explore the effect of new auxiliary chemotherapy before operation on treating local mammary cancer of late stage and prolonging the life of the cancer patients.
结论宫颈癌术前新辅助化疗可改善临床症状，减小肿瘤的体积和范围，降低肿瘤临床分期，提高手术率。
Conclusion: Neoadjuvant chemotherapy can improve the clinical symptom and diminish the volume of the tumors, which can make the clinical stage lower and do the benefit for the radical operation.
方法：对11例四肢骨肉瘤患者进行保肢治疗，其中11例进行了术前、后新辅助化疗。
Method: 11 patients with the diagnosis of osteosarcomas of the extremities were treated with adjuvant chemotherapy and limb salvage surgery.
术前辅以新辅助化疗，术后辅以正规内分泌治疗是提高局部晚期乳腺癌生存率的必要手段。
The neoadjuvant chemotherapy and regular endocrine therapy are the necessary measures to improve the survival rates of locally advanced breast cancer.
乳腺癌术前化疗即新辅助化疗，使局部进展期乳腺癌的治疗取得了重大进展。
Nowadays, neoadjuvant chemotherapy, which is raised by clinic, made a big breakthrough in breast cancer partial treatment progression.
结果：新辅助化疗后，观察组术前肿瘤病灶临床完全缓解（CR）9例，部分缓解（PR）37例。
Results:In study group, after neoadjuvant chemotherapy, 9 cases achieved clinical complete response (CR) and 37 cases achieved partial response (PR).
目的探讨术前新辅助放化疗在可切除食管癌治疗中的作用。
Objective To explore the effect of pre-operative adjuvant chemo-radiotherapy and surgical treatment on resectable esophageal cancer.
肿瘤切除术前的新辅助化疗方案现已成为了肝母细胞瘤(HB)的一项主要治疗手段。
Neoadjuvant chemotherapy followed by resection has become the mainstay in the treatment of hepatoblastoma (HB).
肿瘤切除术前的新辅助化疗方案现已成为了肝母细胞瘤(HB)的一项主要治疗手段。
Neoadjuvant chemotherapy followed by resection has become the mainstay in the treatment of hepatoblastoma (HB).
应用推荐